News & Articles

The real-time PCR system aims to accelerate coronavirus research and diagnostics

Clinical laboratories certified to perform high complexity tests under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this ELISA

Register today to reserve a place at the Summit - it opens at 13:00 (BST) / 14:00 (CEST) / 08:00 (EDT) / 05:00 (PDT) on Monday, May 11

AMSBIO's new service utilizes their novel lentiviral system to aid the development of therapeutic drugs and vaccines

The U.S. Food and Drug Administration has approved Tabrecta (capmatinib) to treat adult patients with non-small cell lung cancer

Preliminary results from a government-sponsored study suggest that drug used to treat Ebola may help COVID-19 patients

Innovosens building partnerships to accelerate development, testing and market launch

The blood-based immunoassay test enables clinicians to identify the virus linked with COVID-19

Discover the latest research applications using multiplex technology to maximize sample use, while saving time and money

The serology test promises 100% sensitivity and can help assess patients' immune response to the virus

The molecular test kit promises 100% diagnostic sensitivity and specificity, and is authorized for clinical practice use in Europe

The antibody test, which has a potential time to result of 14 minutes, will join the rest of the company's diagnostic portfolio

The company aims to provide solutions for the pandemic through close collaboration with scientists and providing cutting-edge laboratory equipment

Learn more about how BINDER is helping countless laboratories across the world conduct research into coronavirus.

Collaboration will enable global development, manufacturing and distribution of the vaccine

These models aim to accelerate treatment development prior to clinical trials

The test will be available for qualified laboratories across the European Union by the end of May

The MicronJet microneedle device to enable the development of a safe, effective and affordable vaccine

Leinco Technologies will co-develop a rapid, point of care, immunodiagnostic test for the detection of the SARS-CoV-2 virus responsible for COVID-19